title: PET-CT: reliable cornerstone for Hodgkin lymphoma treatment?
abstract: In this issue of Blood, Barrington et al present the analyses of centrally reviewed positron emission tomography-computed tomography (PET-CT) used for staging and response monitoring after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) to guide treatment modification in a large prospective clinical trial in Hodgkin lymphoma (HL) (Response-Adapted Therapy in Advanced Hodgkin Lymphoma [RATHL]).
authors.affiliation: VU UNIVERSITY MEDICAL CENTER.
authors.forename: Josée M
authors.identifier: http://orcid.org/0000-0003-1074-5922
authors.initials: JM
authors.lastname: Zijlstra
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*